In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)
Protection against ROS is probably due to the protective cytokines and other products by ADSCs, such as IGF, which can prevent oxidation damage on fibroblasts
Not intended for children, pregnant, and nursing women
Fluid Overload If too much fluid is given too fast, or if the patient has an underlying heart or kidney problem, theres a risk of fluid overload